Switching to ORLADEYO

People who switched to
ORLADEYO® from an injectable
preventative treatment consistently
saw success in controlling attacks

— Kurtis, switched to ORLADEYO in 2021

Individual results may vary

Kurtis, a real person with hereditary angioedema (HAE) that takes ORLADEYO®
People with HAE who have switched to ORLADEYO® had 98% attack-free days

In a study, people who switched from an injectable
preventative treatment to ORLADEYO enjoyed

In a study, people taking ORLADEYO

People with HAE who have switched to ORLADEYO® had 98% attack-free days

after switching from an injectable preventative treatmenta

aThese data are from an analysis of patients who switched from lanadelumab to ORLADEYO during a long-term safety study (n=21). It is unknown what attack rates would have been for these patients had they remained on their previous treatment.

People are switching to—and staying on—ORLADEYO, all because it’s meeting their expectations

Start the conversation with your healthcare provider about joining more than 2,500 people who have been prescribed ORLADEYO

Download the discussion guide and use it to talk to your healthcare provider about where you are in your journey, your satisfaction with your current treatment plan, and if ORLADEYO may be right for you.

Currently taking HAE preventative therapy

Currently taking preventative therapy

Not yet taking HAE preventative therapy

Not yet taking preventative therapy

Le‘ah is talking about why she made the move to ORLADEYO

Hear her story.

Ready to get started?

Learn what making the switch to ORLADEYO looks like from different perspectives

Ready to get started?

INDICATION AND IMPORTANT SAFETY INFORMATION

WHAT IS ORLADEYO® (berotralstat)?

ORLADEYO (or-luh-DAY-oh) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children 12 years of age and older. It is not known if ORLADEYO is safe and effective in children under 12 years of age.

It is not known if ORLADEYO is safe and effective to treat an acute HAE attack, therefore ORLADEYO should not be used to treat an acute HAE attack.

Do not take more than one capsule of ORLADEYO per day because extra doses can cause heart rhythm problems.

IMPORTANT SAFETY INFORMATION

Before taking ORLADEYO, tell your healthcare provider about all of your medical conditions, including if you

  • have liver problems or are on kidney dialysis.
  • are pregnant or planning to become pregnant. It is not known if ORLADEYO can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ORLADEYO passes into your breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking ORLADEYO.

Tell your healthcare provider about all of the medicines you take, including other medicines for HAE, prescription and over-the-counter medicines, vitamins, and herbal supplements.

Taking ORLADEYO with certain other medicines may affect the way other medicines work and other medicines may affect how ORLADEYO works.

Know the medicines you take and keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

What are the possible side effects of ORLADEYO?

Taking more than one capsule of ORLADEYO per day may cause serious side effects, including heart rhythm problems. A heart rhythm problem called QT prolongation can happen in people who take more than one capsule of ORLADEYO per day. This condition can cause an abnormal heartbeat. Do not take more than one capsule of ORLADEYO per day.

The most common side effects of ORLADEYO include abdominal pain, vomiting, diarrhea, back pain, and heartburn. These are not all of the possible side effects of ORLADEYO. For more information, ask your healthcare provider or pharmacist.

Talk to your healthcare provider for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to BioCryst Pharmaceuticals, Inc at 1-833-633-2279 or to the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

For more information, please see the full Prescribing Information including the Patient Information.